Project Grant R01HL181422
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Wisconsin–Madison a Project Grant totaling $639,822 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, with a completion date of June 30, 2029. This research project investigates the role of neutral sphingomyelinase (NSMase), a membrane enzyme involved in sphingolipid metabolism, in cardiac mechanosensing and signal transduction. The research...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Wisconsin-Madison a Project Grant of $151,040 under the Cardiovascular Diseases Research program (CFDA 93.837) on February 5, 2026, with completion targeted for August 31, 2026. This fellowship training award supports research investigating the assembly and localization of human ether-à-go-go-related gene (hERG) channel cotranslational complexes in cardiac tissue. The project aims to...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $521,101 Project Grant to the University of Wisconsin-Madison on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) with a completion date of February 28, 2031. This grant supports research investigating the role of macrophages and hematopoietic stem cell (HSC) trogocytosis in the bone marrow niche. The research focuses on understanding how HSCs acquire macrophage-associated...
- Federal Project Grant Summary The University of Washington received a $663,578 Project Grant award dated August 15, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research through May 31, 2029, addressing diagnostic challenges in inflammatory and genetic cardiomyopathies, specifically cardiac sarcoidosis. The project delivers comprehensive "deep phenotyping" services combining genetic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Wisconsin–Madison a $1.45 million Project Grant on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a five-year research initiative concluding May 31, 2031. The award supports mechanistic research into sex-specific cerebrovascular dysfunction in metabolic syndrome, with the primary objective of identifying subclinical changes in cerebral blood...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Medical College of Wisconsin, Inc. a Project Grant totaling $1,221,260 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for May 31, 2030. The research project, titled "Post-Transcriptional Regulation of Vascular Homeostasis by RNA-Binding Proteins," focuses on identifying and characterizing key regulators of vascular...
- Federal Project Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $651,349 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of May 31, 2029. This award funds research investigating stoichiometric, adhesion, and contractile deficits in desmoplakin cardiomyopathy, a condition caused by genetic...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington a $1.66 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective September 24, 2025, through June 30, 2029, to conduct proteomic and genomic discovery research targeting atrial cardiopathy-related cardiovascular outcomes. The research leverages proteomics and genomic methods across diverse primary and secondary prevention populations to identify...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $776,791 Project Grant to The Washington University on June 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating how sequence changes in intrinsically disordered regions (IDRs) of cardiac troponin affect protein function and cardiac contraction regulation. The project, which extends through April 30, 2029, addresses a critical gap in...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $694,754 Project Grant to The Washington University, Office of Sponsored Research Services, effective August 1, 2025, through May 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative focuses on developing a mechanism-based precision medicine approach for treating cardiomyopathies by connecting molecular and cellular contractile dysfunction to patient...
The University of Wisconsin-Madison received a $747,262 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 1, 2026, and scheduled for completion February 28, 2030. This award supports research aimed at defining the multi-omics landscape of phospholamban-induced dilated cardiomyopathy (DCM) to advance precision medicine approaches. The project utilizes top-down proteomics technology to characterize proteoforms—protein variants resulting from post-translational modifications, genetic variants, and alternative splicing—in phospholamban-R14 deletion (PLN-R14DEL) carriers, examining changes in calcium-handling, contractile, and metabolic proteoforms using both human patient cardiac tissue and human-induced pluripotent stem cell-derived cardiomyocytes. The research deliverables are designed to bridge the genotype-phenotype gap in DCM, addressing the substantial clinical variability observed in PLN-R14DEL carriers that ranges from severe early-onset disease to lifelong asymptomatic presentation. By identifying dysregulated proteoforms and their associated pathways, this funded research will generate critical mechanistic insights into how genetic mutations contribute to variable disease phenotypes and expressivity, thereby supporting the development of precision medicine interventions for one of the leading genetic causes of heart failure and dilated cardiomyopathy.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $747.3k | 6/15/26 |